Physician profile
Douglas E Schreck
NPI 1568558245
$4,089.06
in general payments reported to CMS, 2019-2025
29 companies · $835 in 2025
The $835 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,433 · 2020: $696 · 2021: $105 · 2022: $148 · 2023: $329 · 2024: $544 · 2025: $835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,707.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,707.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $524.80 | 2019-2025 | |
| Boston Scientific Corporation | $334.11 | 2020-2025 | Farapulse, Emblem Mri S-Icd |
| Medtronic, INC. | $329.01 | 2021-2025 | Micra, Corevalve Evolut R |
| Astrazeneca Pharmaceuticals Lp | $305.91 | 2019-2024 | Farxiga |
| Amgen INC. | $291.63 | 2019-2024 | Repatha |
| Abbott Laboratories | $283.85 | 2020-2025 | Navitor, Aveir, Triclip |
| Boehringer Ingelheim Pharmaceuticals, INC. | $282.53 | 2019-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $199.39 | 2019-2024 | Lifevest |
| Akcea Therapeutics, INC. | $185.72 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $182.44 | 2019-2025 | Camzyos, Eliquis |
| Penumbra, INC. | $147.52 | 2023 | Indigo System |
| Janssen Pharmaceuticals, INC | $140.93 | 2019-2021 | |
| Pfizer INC. | $136.43 | 2019-2025 | |
| Amarin Pharma, INC. | $112.79 | 2019 | |
| Edwards Lifesciences Corporation | $93.48 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $69.79 | 2023-2024 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $65.01 | 2019 | |
| Irhythm Technologies, INC. | $63.66 | 2019-2024 | Zio Xt Patch, Zio Monitor |
| Lantheus Medical Imaging, INC. | $50.00 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $45.32 | 2019 | |
| Heartflow, INC. | $40.87 | 2025 | |
| Sanofi-Aventis U.S. LLC | $40.68 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $29.98 | 2024 | Arcalyst |
| Philips North America LLC | $27.65 | 2024 | (5044) Mcot |
| Cvrx, INC. | $26.48 | 2024 | Barostim Neo System |
| Baxter Healthcare | $25.00 | 2019 | |
| Ge Healthcare | $22.28 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.62 | 2025 | |
| Getinge USA Sales, LLC | $12.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Schreck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.